Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Endocrinology
•
Pituitary Disorders
•
General Endocrinology
When do you recommend using L-arginine stimulated copeptin testing to evaluate for central diabetes insipidus (AVP-deficiency)?
Related Questions
Does norethindrone suppress FSH, LH completely?
Should we be considering transsphenoidal surgical resection as first-line therapy for prolactinomas?
Do patients with an elevated IGF-1 level and features of acromegaly need to have confirmatory growth hormone suppression testing with OGTT?
How do you approach mild prolactin elevations (20-80) in women with galactorrhea on nipple stimulation but regular menses and no plans for pregnancy?
Given the new 2022 WHO classification of pituitary tumors, should we be regularly counseling our patients about the risk of malignancy for what we previously referred to as pituitary adenomas but now classified as pituitary neuroendocrine tumors (PitNETs)?
How do you adjust your HbA1c goal for managing diabetes in elderly patients with multiple chronic illnesses but no limitations in performing self-care tasks?
What is your approach to differentiating pseudo-Cushing's state from Cushing's syndrome?
What is your approach to managing patients with new laboratory evidence of hypopituitarism (e.g. very low plasma ACTH level and low morning serum cortisol) and a remote history of trans-sphenoidal surgery for NFPA?
When do you check macroprolactin in the evaluation of hyperprolactinemia?
When do you recommend the use of oral testosterone replacement over injectable testosterone?
